Clinical Research Directory
Browse clinical research sites, groups, and studies.
A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity
Sponsor: Novo Nordisk A/S
Summary
The purpose of the study is to find out if NNC0721-8060 is safe and how it works in people living with overweight or obesity.
Official title: A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0721-8060 in Healthy Adult Participants Living With Overweight or Obesity
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
142
Start Date
2026-08-12
Completion Date
2027-09-23
Last Updated
2026-09-04
Healthy Volunteers
Yes
Conditions
Interventions
NNC0721-8060
NNC0721-8060 will be administered subcutaneously.
Semaglutide
Semaglutide will be administered subcutaneously.
Placebo
Placebo will be administered subcutaneously.
Locations (2)
ICON Early Phase Services, LLC
Lenexa, Kansas, United States
ICON
San Antonio, Texas, United States